Syn-Ake acetate

CAS No. 823202-99-9

Syn-Ake acetate( Dipeptide diaminobutyroyl benzylamide )

Catalog No. M21165 CAS No. 823202-99-9

Syn-Ake acetate is a muscarinic acetylcholine receptor antagonist.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 29 In Stock
100MG 45 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Syn-Ake acetate
  • Note
    Research use only, not for human use.
  • Brief Description
    Syn-Ake acetate is a muscarinic acetylcholine receptor antagonist.
  • Description
    Syn-Ake acetate is a muscarinic acetylcholine receptor antagonist.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Dipeptide diaminobutyroyl benzylamide
  • Pathway
    Endocrinology/Hormones
  • Target
    AChR
  • Recptor
    Muscarinic AChR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    823202-99-9
  • Formula Weight
    495.58
  • Molecular Formula
    C19H29N5O3.2(C2H4O2)
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:3mg/ml(6.05mM)
  • SMILES
    CC(=O)O.CC(=O)O.NCCC(=O)N1CCCC1C(=O)NC(CCN)C(=O)NCc1ccccc1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Balaev A N Okhmanovich K A Osipov V N . A shortened protecting group free synthesis of the anti-wrinkle venom analogue Syn-Ake? exploiting an optimized Hofmann-type rearrangement[J]. Tetrahedron Letters 2014 55(42):5745-5747.
molnova catalog
related products
  • NS 1738

    NS 1738 is a positive allosteric modulator of the α7-containing neuronal nicotinic acetylcholine receptors (nAChRs).

  • Galanthamine N-Oxide

    Galanthamine N-Oxide inhibits electric eel acetylcholinesterase (AChE) with an EC50 of 26.2 μM.?

  • Galanthaminone

    Galanthaminone is a cholinesterase (AChE) inhibitor?is used for the treatment of mild to moderate Alzheimer's disease and various other memory impairments.